Hep C Discussion Forum

Members Login
Username 
 
Password 
    Remember Me  
Chatbox
Please log in to join the chat!
Post Info TOPIC: Interferon-free combo Faldaprevir and Deleobuvir with ribavirin achieves 95% cure rate in geno 1b


Guru

Status: Offline
Posts: 3398
Date:
RE: Interferon-free combo Faldaprevir and Deleobuvir with ribavirin achieves 95% cure rate in geno 1b
Permalink  
 


Hi Jill,

I don't know about you, but my head is starting to spin with the new DAA's. I obviously don't understand, but why are we looking at drug combos that are useful in Geno 1b but not 1a?† In the USA, about 60% of HCV patients have Geno 1a as opposed to only 17% who have Geno 1b. I also don't understand why studies are done on drugs that still require a favorable Interleukin 28B allele (CC). Antiproteases cause problems because they block some other protease sites in the body, not just in the HCV. Incivek is out of favour due to the deaths from rashes and Victrelis sales have soared. If antiproteases must be used, why not stick with Victrelis which now has been used extensively. † By using a NS5A blocker, the problem of IL28B status is removed, as this is the viral site responsible for Interferon sensitivity( and possibly Riba).

To my simple mind, Boehringer- Ingelheim are just wasting their money and making it more difficult for us to follow the real DAA contenders.



__________________

Geno 1b, IL28B CT,† x3 prior relapser,† ex-cirrhotic, 75 yo, did 48 weeks with Victrelis/Peg./Riba.† VL 1.28m at start, UNDET. at 8 ,12 ,16 ,24 ,30† and 48 weeks.† EOT 15 Feb 2013 , UNDET. at EOT + 28 weeks. SVR! Still Undet. at EOT +5 years

Malcolm



Guru

Status: Offline
Posts: 5627
Date:
Permalink  
 

Faldaprevir and deleobuvir with ribavirin achieves 95% cure rate in geno 1b

Interferon-free combo faldaprevir+ and deleobuvir+ (BI 207127)/ribavirin achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim`s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naÔve patients with genotype-1b (GT-1b) hepatitis C virus (HCV), one of the most common types of HCV globally.

http://www.hepctrust.org.uk/News_Resources/news/2013/June/Faldaprevir+and+deleobuvir+achieves+95+cure+rate+in+geno+1b



__________________

Jill†

(71 yo, lives in UK)

Was Gen 3a,†

24wks Peg Ifn/Riba, Sep 2010 - Mch 2011

UND @ Wk.4, UND @ EOT,†

SVR Nov 2011 --> Still UND @ EOT + 4 yrs.

Page 1 of 1  sorted by
 
Quick Reply

Please log in to post quick replies.

Legal Disclaimer:

THIS FORUM, IT'S OWNERS, ADMINISTRATORS, MODERATORS AND MEMBERS DO NOT AT ANY TIME GIVE MEDICAL ADVICE AND IN ALL CASES REFER ANYONE HERE TO SEEK APPROPRIATE MEDICAL ADVICE FROM THEIR DOCTOR.